ALDX:NSD-Aldeyra Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 6.71

Change

-0.32 (-4.55)%

Market Cap

USD 0.27B

Volume

0.36M

Average Target Price

USD 15.00 (+123.55%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-11.73 (-7.68%)

USD60.44B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+2.55 (+1.12%)

USD59.22B 22.32 17.39
REGN Regeneron Pharmaceuticals, Inc

-1.96 (-0.38%)

USD55.06B 18.91 14.53
SGEN Seagen Inc

+7.10 (+4.17%)

USD30.48B 64.32 62.62
BNTX BioNTech SE

-10.23 (-8.23%)

USD29.92B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+0.04 (+0.03%)

USD26.72B 28.34 26.92
RPRX Royalty Pharma plc

+0.18 (+0.42%)

USD26.64B 22.60 9.74
GMAB Genmab A/S

-0.37 (-0.96%)

USD25.29B 26.59 2.61
BGNE BeiGene, Ltd

-9.20 (-3.60%)

USD21.65B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.49% 56% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.49% 56% F 65% D
Trailing 12 Months  
Capital Gain 32.61% 58% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.61% 58% F 70% C-
Trailing 5 Years  
Capital Gain -6.81% 61% D- 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.81% 61% D- 32% F
Average Annual (5 Year Horizon)  
Capital Gain 4.99% N/A N/A 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.99% N/A N/A 49% F
Risk Return Profile  
Volatility (Standard Deviation) 42.42% N/A N/A 29% F
Risk Adjusted Return 11.76% N/A N/A 40% F
Market Capitalization 0.27B 48% F 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.78 53% F 36% F
Price / Cash Flow Ratio -6.07 48% F 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -65.68% 50% F 18% F
Return on Invested Capital -82.78% 33% F 11% F
Return on Assets -28.63% 47% F 13% F
Debt to Equity Ratio 30.22% 38% F 55% F
Technical Ratios  
Short Ratio 2.77 63% D 55% F
Short Percent 4.82% 59% F 39% F
Beta 2.04 23% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector